• Home
  • Contact Us!
  • Privacy Policy

Radio Metta

  • Home
  • Business
  • Education
  • Health
  • Home Deco
  • News
  • Real Estate
  • Technology
  • Contact Us!
  • Privacy Policy
Home» Health»Doctors often overestimate promise of newly approved drugs

Doctors often overestimate promise of newly approved drugs

Saheli 13 Apr 2016 Health Comments Off on Doctors often overestimate promise of newly approved drugs 18 Views

TUESDAY, April 12, 2016 — Use of the word “breakthrough” in the U.S. Food and Drug Administration’s expedited approval process could mislead doctors about the new drugs’ actual benefits, researchers warn.

The U.S. Congress in 2012 gave FDA the power to designate a drug as a “breakthrough therapy” if preliminary clinical evidence suggests an advantage over existing medications.

But a survey of nearly 700 doctors revealed that many tended to misinterpret “breakthrough.” Doctors often believed the drugs were supported by stronger evidence than the law requires to achieve that designation, said lead author Dr. Aaron Kesselheim. He is a faculty member at Brigham and Women’s Hospital in Boston.

“When people hear ‘breakthrough,’ it gives them an inappropriately elevated sense of what the drug might do,” Kesselheim said. “It may give physicians false reassurance about the outcomes they might expect to receive when they prescribe it.”

In the survey, nine out of 10 doctors chose one hypothetical drug over another identical one solely based on the “breakthrough” designation, even though both were taken on the same schedule, had similar side effects, and were equally covered by the patient’s insurance.

In addition, 52 percent incorrectly believed that strong evidence from randomized trials is needed to earn the breakthrough designation, the researchers found.

“They thought when a drug is labeled as a breakthrough therapy it actually is a breakthrough, and that’s not necessarily the case,” Kesselheim said. “Many drugs labeled as breakthrough therapies are not true breakthroughs, because they don’t provide substantially advanced treatment over what’s already available.”

The results were published April 12 in the Journal of the American Medical Association.

The FDA designated 76 drugs as “breakthrough therapies” through April 2015, the researchers noted, but very few have had a major impact on the health of Americans.

“It would be great if all of those drugs actually were breakthroughs, but the likelihood of that is very small,” Kesselheim said.

Dr. Robert Wergin, chair of the American Academy of Family Physicians, agreed there can be confusion over the use of the word “breakthrough.”

“A lot of times when drug companies send me advertisements that say ‘breakthrough,’ I’m skeptical,” Wergin said. “When I first hear it, I think it’s marketing. But if the FDA is using it, I don’t think it’s marketing. I think they should be cautious with it.”

The survey also revealed a widespread lack of understanding about the meaning of FDA approval for a new drug, the researchers reported.

For example, about seven in 10 believed FDA approval meant comparable effectiveness to other approved drugs, and statistically significant and clinically important effects.

“When a drug is approved, it’s not necessarily tested against other available drugs,” Kesselheim said. “It may be tested against placebo. Just because a drug is approved doesn’t mean it’s better or safer than other drugs already out there.”

Congress and the FDA should revisit the use of the term “breakthrough” in the expedited program, Kesselheim said.

“I wouldn’t be averse to calling true breakthroughs ‘breakthroughs,’ but that’s not currently what we’re doing,” he said.

The FDA released the following statement in response to the study: “In general, the FDA does not comment on specific studies, but evaluates them as part of the body of evidence to further our understanding about a particular issue and assist in our mission to protect public health.”

Dr. Otis Brawley, chief medical officer for the American Cancer Society, said the survey did not capture one important piece of the puzzle — that doctors often learn a lot about new drugs before they get to FDA approval, either through their medical societies or by talking among themselves.

Brawley also said he is “convinced there are still some doctors who still tend to think the new drugs are better than the old drugs.”

He noted the case of Prilosec, a heartburn medication made by AstraZeneca. When it came time for Prilosec to go generic, AstraZeneca marketed a new heartburn drug called Nexium for which it could still charge premium prices.

“They never said that Nexium simply contained the same active ingredient as their old drug Prilosec,” Brawley said. “If you’ll recall, Nexium became one of the best-selling drugs for years. There are people who are surely prescribing it because it is newer.”

[Source:- UPI]

approved Doctors drugs newly of often overestimate promise 2016-04-13
Tags approved Doctors drugs newly of often overestimate promise
Facebook Twitter Stumble linkedin Pinterest More

Authors

Posted by : Saheli
Previous Article :

Oil prices increase, though IMF outlook could erase rally

Next Article :

The Apartments

Related Articles

Firefly Health Taps Oshi Health to Add Whole-Person Digestive Care to Its Virtual Specialty Network

Loknath Das 06 Jun 2022

This Relentless Pandemic Can Tax Your Mental Health. Here’s How to Cope

Loknath Das 11 Apr 2022

Study: Two New Early Signs of Parkinson’s Disease Identified

Loknath Das 05 Apr 2022

Latest Post

News

Your SEO Budget Is Determining Your Success

admin 03 Sep 2022
News

WAN Connection Method – Frame Relay

admin 26 Aug 2022
Education

GESS Proudly Supports and Sponsors UAE Based Team in Global STEM Challenge

Loknath Das 28 Jul 2022
Technology

The Samsung Galaxy Z Flip4 gets FCC certification

Loknath Das 22 Jul 2022
Education

USF faculty, students to present at 2022 American Educational Research Association Annual Meeting

Loknath Das 22 Jul 2022
Technology

“Critical” We Understand Digital Money’s Impact: US Policymaker

Loknath Das 07 Jun 2022
Health

Firefly Health Taps Oshi Health to Add Whole-Person Digestive Care to Its Virtual Specialty Network

Loknath Das 06 Jun 2022
September 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
« Sep    
  • Home
  • Contact Us!
  • Privacy Policy
Copyright 2016, All Rights Reserved
Magazine Blog News WordPress Theme